[Chemotherapy-selective nodal irradiation in Hodgkin's disease clinical stages IA-IIIB. Results of a prospective clinical trial including 334 patients (author's transl)].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D006689:Hodgkin Disease / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D008198:Lymph Nodes / Q000528:radiation effects; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D011446:Prospective Studies; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D011241:Prednisone
La séquence polychimiothérapie MOPP-irradiation ganglionnaire sélective dans le traitement de la maladie de Hodgkin, stades cliniques IA-IIIB. Résultats à 8 ans d'un protocole prospectif comportant 334 patients.